Beam Therapeutics and Bio Palette Announce Exclusive License Agreements for Base
Editing Technologies
Bio Palette licenses base editing intellectual property to Beam Therapeutics for use in humantherapeutics
Beam Therapeutics licenses base editing intellectual property to Bio Palette for use in
microbiome-related therapeutics in Asia

Cambridge, Mass. and Kobe City, Japan – May 31, 2019 – Beam Therapeutics and Bio
Palette today announced an exclusive cross-license agreement around each companies’ baseediting intellectual property.
Bio Palette, a Japanese biotechnology company, is developing new genome editing technologies
for use in various fields, including agriculture and the microbiome. Bio Palette has licensed baseediting intellectual property from Kobe University, which was invented by Drs.
Keiji Nishida and Akihiko Kondo.
Beam Therapeutics, a U.S.-based biotechnology company, is developing precision genetic
medicines through base editing. Beam has licensed its foundational base editing intellectual
property from Harvard University, the Broad Institute, MIT and Editas Medicine across multiple
base editing platforms.
Under the terms of its agreement with Beam, Bio Palette is granting Beam an exclusive license
to develop Bio Palette’s intellectual property in the field of human therapeutics, with theexception of rights to microbiome related therapeutics in Asia, which are retained by Bio Palette.
In addition, Beam is granting Bio Palette an exclusive license to IP from its foundational license
agreements to develop microbiome-related therapeutics in Asia. In order to strengthen thecompetitive position of both Parties, the Parties intend to work together to leverage Bio Palette’sexperience and expertise in Japan. Bio Palette agrees to assist Beam in developing relationships
in Japan, and to advise on Beam’s business development strategy in Japan.
“We are very pleased to enter into this strategic cross-licensing agreement with Bio Palette, withboth parties benefiting in our respective areas of base editing expertise. This agreement further
strengthens our leadership position in developing base editing for human therapeutics, and will
enable Beam to take advantage of Bio Palette’s unique and valuable expertise in Japan,” said
John Evans, CEO of Beam Therapeutics.
“Base editing is an important potential therapeutic approach in the microbiome. As we are bothpioneers in base editing, Beam Therapeutics is a natural partner for Bio Palette as we continue toenhance our focus on the development of microbiome-based therapeutics, and to be a global
leader in this field,” said Prof. Akihiko Kondo, director of Bio Palette.

Financial terms of the agreement include an undisclosed upfront payment to Bio Palette fromBeam, an equity position in Beam by Bio Palette, and royalties from sales of commercialized
products by Beam or Bio Palette to the other party.
About Beam Therapeutics
Beam Therapeutics is developing precision genetic medicines through base editing. Founded byleading scientists in CRISPR gene editing, Beam is pursuing therapies for serious diseases using
its proprietary base editing technology, which can make precise edits to single base pairs in DNAand RNA. Beam is headquartered in Cambridge, Massachusetts. For additional information, visit
www.BeamTx.com.
About Bio Palette
Bio Palette was set up to commercialize its unique base editing technologies licensed from Kobe
University. Bio Palette is pursuing business collaborations globally, focusing on the field of
microbiome therapeutics, agriculture, or microbes. Bio Palette is located in Kobe City, Japan.
For additional information, visit www.biopalette.co.jp